30 studies found for:    " October 30, 2011":" November 29, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Download search resultsDownload the search results for:
" October 30, 2011":" November 29, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION] (30 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: RTV;   Drug: TVD;   Drug: PI
2 Unknown  Bioequivalence Study of Pediatric Formulations to Treat HIV Infection
Conditions: HIV;   AIDS
Interventions: Drug: Epivir®, Retrovir® and Viramune®;   Drug: Lamivudine, Zidovudine and nevirapine;   Drug: Lamivudine, zidovudine, nevirapine
3 Active, not recruiting Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Conditions: Tobacco Cessation;   HIV;   AIDS
Interventions: Behavioral: Treatment as usual;   Behavioral: AIR (Aspirations, Inspiration, Respiration)
4 Completed A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
Condition: HIV Infection
Interventions: Drug: Vaccination;   Drug: Placebo
5 Completed Intranasal Modified Vacc-4x Gag Peptides With Endocine as Adjuvant
Condition: HIV Infection
Interventions: Biological: Vacc-4x low dose;   Biological: Vacc-4x medium dose;   Biological: Vacc-4x high dose;   Biological: Zero dose
6 Completed Atazanavir/Ritonavir and Zinc Pharmacokinetic Study
Condition: HIV Infection
Interventions: Drug: 1 Solvazinc tablet, day 2 to day 15;   Drug: 1 Solvazinc tablet, day 15 to day 28
7 Terminated Investigation of The Effect of Cenicriviroc (CVC) Plus FTC/TDF on Cardiovascular Disease Risk Factors
Condition: HIV Infection
Intervention:
8 Withdrawn Trial of Probiotics to Lower Microbial Translocation and Immune Activation in HIV-Infected Adolescents
Condition: HIV Infection
Interventions: Dietary Supplement: Probiotics;   Dietary Supplement: Placebo
9 Recruiting On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men
Condition: HIV Infection
Interventions: Drug: Truvada;   Drug: Placebo
10 Completed Efficacy of Raltegravir in a Large Urban HIV Clinical Population in Milan
Condition: HIV Infections
Intervention:
11 Completed Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Condition: HIV-1 Infection
Interventions: Drug: Isentress® (Raltegravir, 400 mg every 12 hours);   Drug: Isentress® (Raltegravir, 400 every 12 hours)
12 Recruiting Comorbidity and Aging With HIV
Conditions: HIV-1-infection;   Comorbidity;   Ageing
Intervention:
13 Completed A Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 and Rilpivirine and Dolutegravir and Rilpivirine in Healthy Adult Subjects
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir;   Drug: Rlipivirine;   Drug: GSK1265744
14 Completed Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression
Condition: HIV Infection
Intervention: Drug: antiretroviral treatment
15 Active, not recruiting Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
16 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
17 Completed A Study of MK-1439 in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)
Condition: HIV-1 Infection
Interventions: Drug: MK-1439;   Drug: Placebo
18 Suspended Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation
Condition: HIV-1 Infection
Interventions: Drug: Pravastatin sodium;   Drug: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
19 Recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
20 Completed Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
Condition: Infections, Human Immunodeficiency Virus and Hepatitis
Interventions: Drug: Dolutegravir;   Drug: Methadone

Previous Page Studies Shown (1-20) Next Page (21-30) Show next page of results
Indicates status has not been verified in more than two years